ClinicalTrials.gg
CompletedNCT03579381Updated Jan 12, 2021

Specimen Repository for HIV Immunopathogenesis

An observational study in HIV-1-infection and Acute HIV Infection, sponsored by AIDS Healthcare Foundation. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by AIDS Healthcare Foundation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
9
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,803 studies in HIV Infections with a site in United States — 84 open to participants now, 141 under way, 11 of them phase 3. HIV Infections · United States.

Enrollment
335th of 350
9 · median 135
Started
2017
with 40 others
Observational
357 of 2,803
12 open now
Registered
2,443rd of 2,803
by date

Among the 2,803 studies in HIV Infections with a site in United States, this one is the 335th largest by enrollment of the 350 observational ones that give a count, is one of 41 that started in 2017, is one of 357 observational ones, and was the 2,443rd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

84 of the 2,803 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,803 studies in HIV Infections with a site in United States, or all of them as a file.
02

Study summary

Specimen Repository for HIV Immunopathogenesis Studies

Read the detailed description

The goal is to build a large specimen repository for collaborating scientists to run studies of immunity and HIV-1.

03

Conditions studied

  • HIV-1-infection
  • Acute HIV Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Acutely HIV infected individuals HIV infected individuals who are not on anti-retrovirals and have a viral load between 50 and 3,000 HIV infected individuals who are not on anti-retrovirals and have a viral load less than 49

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. positive (acutely infected, viremic and elite controllers)
  2. Signed Form
  3. Age at least 18 years old
  4. Immune controllers, two types: "Elite suppressors" (HIV-positive with any three consecutive plasma HIV-1 RNA PCR undetectable while off treatment) or "viremic suppressors" (HIV-positive with any three consecutive HIV-1 RNA PCR \<3000 while off treatment).
  5. Acutely infected subjects:

Persons identified to have a negative HIV antibody response (ELISA) but positive detection of HIV-1 in the blood (RT-PCR) or individuals who have evidence of a recent (past 30 days) HIV negative result along with a current HIV positive result.

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled bleeding diathesis.
  2. Pregnant.
  3. Inability to provide .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
9 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Immune Controllers

    Patients with very low or undetectable levels of viremia without treatment

  • Acute Infection

    Early infection, i.e. within 2 weeks of infection

06

What researchers measure

Primary outcomes

  1. HIV progression from acute infection to viral suppression

    Outcomes will depend on scientists who use the samples for further study

    Time frame: 2 years

  2. HIV progression and control by elite and viremic suppressors

    Outcomes will depend on scientists who use the samples for study

    Time frame: 2 years

07

Study locations

1 site
  • AIDS Healthcare Foundation - Public Health Division
    Los Angeles, California 90027, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jan 2019, 17 months.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's 17 months is below that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2018
First posted
Jul 6, 2018
StartActual
Jul 31, 2017
Primary completionActual
Jan 25, 2019
CompletionActual
Jan 25, 2019
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03579381
Lead sponsor
AIDS Healthcare Foundation
Responsible party
Sponsor
First posted
Jul 6, 2018
Start date
Jul 31, 2017
Primary completion
Jan 25, 2019
Completion
Jan 25, 2019
Last update
Jan 12, 2021

Study contacts

Otto O Yang, MD
study director · Scientific Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion